QCM Cayman’s AbbVie ABBV Stock Holding History

QCM Cayman’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,939	Closed	-$278K	–	85
2018 Q1	$278K	Buy	+2,939	New	+$323K	0.72%	53
2017 Q3	–	Sell	-3,389	Closed	-$246K	–	147
2017 Q2	$246K	Buy	+3,389	New	+$228K	0.56%	88
2016 Q4	–	Sell	-4,874	Closed	-$307K	–	135
2016 Q3	$307K	Buy	+4,874	New	+$316K	0.34%	74
2016 Q2	–	Sell	-4,309	Closed	-$246K	–	282
2016 Q1	$246K	Buy	+4,309	New	+$240K	0.17%	111

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

QCM Cayman's ABBV Position: Q2 2018 in Review

QCM Cayman sold out of AbbVie (ABBV) in Q2 2018, closing a stake of 2,939 shares — an estimated $278K sold.

QCM Cayman first reported a position in ABBV in Q1 2016 and held it in 4 quarters. The position peaked at $307K in Q3 2016. 1,996 funds tracked by Wall St. Rank hold ABBV as of Q2 2018.

QCM Cayman reported no remaining AbbVie position as of Q2 2018 after selling out during the quarter.
QCM Cayman sold 2,939 AbbVie shares in Q2 2018, an estimated $278K.
QCM Cayman first reported a position in AbbVie in Q1 2016 and held it in 4 quarters.
QCM Cayman's AbbVie position peaked at $307K in Q3 2016.
1,996 funds tracked by Wall St. Rank held AbbVie as of Q2 2018.

Based on QCM Cayman's 13F filing for Q2 2018, filed 14 Aug 2018.